LEADER 01675nam  2200457   450 
001 9910707229603321
005 20160624094802.0
035   $a(CKB)5470000002463214
035   $a(OCoLC)952178269
035   $a(OCoLC)995470000002463214
035   $a(EXLCZ)995470000002463214
100   $a20160624d2011      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 10$aHigher rebates for brand-name drugs result in lower costs for Medicaid compared to Medicare Part D
210  1$a[Washington, D.C.] :$cDepartment of Health and Human Services, Office of Inspector General,$d2011.
215   $a1 online resource (iv, 22 pages) $ccolor illustrations
300   $aTitle from title screen (viewed June 23, 2016).
300   $a"August 2011."
300   $a"OEI-03-10-00320."
320   $aIncludes bibliographical references.
517 1 $aHigher rebates for brand-name drugs result in lower costs for Medicaid compared to Medicare Part D
606   $aMedicare
606   $aMedicaid
606   $aPharmaceutical services insurance$zUnited States$xAuditing
606   $aDrugs$xPrices$zUnited States
606   $aBrand name products$xPrices$zUnited States
615  0$aMedicare.
615  0$aMedicaid.
615  0$aPharmaceutical services insurance$xAuditing.
615  0$aDrugs$xPrices
615  0$aBrand name products$xPrices
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910707229603321
996   $aHigher rebates for brand-name drugs result in lower costs for Medicaid compared to Medicare Part D$93310614
997   $aUNINA